Key Takeaways
- Record quarter, broad-based: Highest-ever quarterly sales and profitability, with total income up 13.9% YoY and PAT up 24.6% YoY, driven by demand across domestic and export markets.
- Margins improved on cost discipline: EBITDA margin reached 27.48% (up 136 bps YoY) as other expenses were held to 9.72% of sales through constant monitoring and better fixed-cost absorption, even with a slight raw material cost uptick.
- Phase 1 capacity is live, Phase 2 funded and on track: Installed capacity rose to 54,000 MTPA; Phase 2 capex is underway with completion by September 2027 and a ~₹1,000 crore revenue contribution expected once it is in full capacity.
- Full-year 20% growth guidance reaffirmed: Management is confident of maintaining or beating 20% revenue growth for FY27, with H2 seasonally stronger and first customer indications positive.
- What to watch next quarter: The pace of Phase 1 capacity utilization ramp-up in Q3, progress on the two undisclosed new partnerships, and closure of the Privi Fine Sciences merger before fiscal year-end.
Quarterly Performance & Margin Drivers
- Revenue growth: Total income grew 13.9% YoY, supported by broad-based demand and the resilience of the business model.
- Profitability leap: PAT grew 24.61% YoY, with EBITDA up 16.66% YoY; the conversion from EBITDA to PAT has improved significantly over the last 4–5 quarters due to better asset utilization and declining interest costs.
- Margin walk: EBITDA margin improved to 27.48% from 26.12% prior year because other expenses were tightly controlled at 9.72% of sales through constant monitoring and optimum capacity utilization, spreading fixed costs over a larger base. Raw material cost as a percentage of sales was 52% vs 51% prior year, a slight increase attributed to CST/GTO sourcing variations across locations.
- State incentives headwind: Only ₹1.62 crores received in H1 FY27 vs ₹9 crores in the prior year; excluding incentives, underlying EBITDA margins still improved due to expense control. Management expects more incentives in the next 6 months, with the FY27 total higher than the previous year.
- Other income boost: Higher other income in Q1 and Q2 FY27 primarily came from foreign exchange gains, as the company is a net exporter and the dollar has been favorable.
- Q2 seasonality: Q2 has been superior over the last 4–5 financial years because second calendar year contracts with some customers often bring newer products, resulting in better margins and profitability.
Babani: "We are confident of maintaining 20% or beating 20%, be honest. We are confident that we'll be able to be close to INR4,000 crores, maybe INR3,750 or some number, but we are close to guidance what we have given. 20% will be surely maintained."
Balance Sheet & Working Capital
- Working capital cycle: Reduced to under 100 days from 124 days YoY; cash from operations reached ₹445 crores in H1, driven by higher profits. The long-term annual expectation is 105–110 days.
- Receivables improvement: Receivables declined vs March while sales moved up because customers have been paying on time or even a few days early, reflecting Privi’s quality and delivery performance.
- Return ratios: ROCE improved 216 bps YoY to 24.30%; ROE up 134 bps to 26.34%.
- Leverage: Net debt-to-EBITDA at 1.07x; net debt-to-equity at 0.51x, indicating a strong balance sheet position.
Iyer: "Privi stands for quality on delivery time, and expectations of the customers have been so good with us that they have been helping us in ensuring that the money is paid to us on time and in some cases, maybe a few days before time also."
Capacity Expansion & Capex Roadmap
- Phase 1 completed: Installed capacity increased from 48,000 MTPA to 54,000 MTPA as of 30 September 2026. Part of the expanded capacity volumes will come through in Q3 FY27, but significant impact is expected in Q4 FY27 when new annual contracts begin; utilization is expected at 85–90% for the expanded capacity in Q4.
- Phase 2 timeline: Furfural-based derivatives (maltol, ethyl maltol, cyclopentanone, and specialty molecules) capex is underway with some expenses already incurred; completion expected between June and September 2027, with revenue contribution starting from October 2027. Full capacity of 12,000 metric tons is expected to contribute ~₹1,000 crores in revenue.
- Phase 3: Capex of ₹400–425 crores, with additional revenue of ₹450–500 crores.
- Combined 3-phase revenue: ~₹1,900 crores, fully in sync by 2030, enabling the company to reach the ₹5,000 crores mark under the 5K:1K plus vision.
- New capacity offtake: During the 1-year project build, products will be manufactured on a pilot basis and sold to customers to sort out quality and other issues before commercial production starts; management described the customer response as positive, very positive.
Patil: "You will see part of it coming through in quarter 3, but a significant part would come in quarter 4 because that's when the new contracts really start, which are annual contracts. So we are very positive about those contracts. And you will see significant impact of that capacity utilization of almost 85% to 90% during that quarter for the expanded capacity also."
Subsidiaries & JVs
- PRIGIV JV: Achieved its first profitable quarter in Q4 FY26 and continued profitability in Q2 FY27; Q2 FY27 sales of ~₹28 crores with positive PBT of ~₹2 crores; H1 FY27 sales of ~₹47 crores with negligible loss. Focus now on scaling and building a higher-value product portfolio. A process of converting debt into advances is in progress with large multinational companies. FY27–28 revenue guidance of ~₹225 crores, with a third phase being studied in pilot that could take it beyond that figure.
- Privi Fine Sciences: Turnover of ~₹68 crores in FY26 with a loss of ~₹34.28 crores; capacity utilization at 85% but full capacity not yet realized due to pending regulatory approvals. Four out of five products are already being supplied to top multinationals. Regulatory approvals are nearing completion, with significant improvement in numbers expected next financial year; once permissions are in place, expansion will drive revenue from ~₹100 crores to the ₹250–300 crores mark. The merger process is expected to be completed before the end of the current financial year.
Market Environment & Competitive Position
- Raw material resilience: ~70% of revenue comes from non-petroleum source raw materials, so geopolitical tensions and freight volatility have limited impact on input costs. CST/GTO sourcing is very diversified.
- End-market growth: Aroma chemicals usage is increasing significantly, with the Africa market growing and new applications and users of pinene emerging.
- European headwinds as opportunity: Regulatory and cost pressures in Europe create opportunities for compliant, quality-conscious Indian manufacturers; Privi is positioned to capitalize on these shifts.
- Next-year contracts: Management described the situation as extremely good with a very positive outlook for the market and customers, though declined to provide specifics, calling the details proprietary.
Babani: "See, our market's usage of aroma chemicals is increasing significantly. Lots of new things are coming, new people are using more and more pinene. Africa market is growing. So for us, we supply to markets -- customers who supply to Africa. So the markets are really growing well, and we hope to maintain the 20% target as committed."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 revenue growth | Maintain or beat 20% growth; revenue close to ₹3,750–4,000 crores | FY27 full year |
| FY27 EBITDA margin | Maintain at current levels | FY27 full year |
| Phase 1 capacity utilization | Ramp to 85–90% for expanded capacity | Q4 FY27 |
| Phase 2 capex completion | Maltol, ethyl maltol, furfural derivatives plant complete; ~₹1,000 crores revenue at full capacity | Completion Jun–Sep 2027; revenue from Oct 2027 |
| Phase 3 capex | ₹400–425 crores capex for ₹450–500 crores additional revenue | In sync by 2030 |
| 5K:1K plus vision | Reach ₹5,000 crores revenue | By 2030 |
| Privi Fine Sciences merger | Merger process completed | Before end of FY27 |
| Privi Fine Sciences revenue scale-up | Revenue from ~₹100 crores to ₹250–300 crores | Next financial year (FY28) |
| PRIGIV JV revenue | ~₹225 crores, with potential upside from a third phase under study | FY27–28 |
| Working capital cycle | 105–110 days | Long-term annual expectation |
| State incentives | Total FY27 higher than previous year | Next 6 months |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Total revenue | ₹773.16 cr, up 13.9% YoY, highest ever quarterly |
| EBITDA | ₹212.49 cr, up 16.66% YoY, highest ever quarterly |
| Profit after tax | ₹117.03 cr, up 24.61% YoY |
| EBITDA margin | 27.48%, vs 26.12% in FY26 |
| H1 FY27 PAT | ₹201 cr, up ~29% YoY |
| RMC as % of sales | ~52%, vs 54% in Q1 FY27 and 51% in Q2 FY26 |
| Other expenses as % of sales | 9.72% |
| State incentives received | ₹1.62 cr in H1 FY27, vs ₹9 cr in H1 FY26; ₹12–15 cr expected in H2 |
| ROCE | 24.30%, improvement of 216 bps YoY |
| ROE | 26.34%, increase of 134 bps YoY |
| Net debt | ₹814.51 cr; net debt-to-EBITDA 1.07x, net debt-to-equity 0.51x |
| Working capital cycle | Less than 100 days, vs 124 days in Q2 FY26; long-term expectation 105–110 days |
| Cash generated from operations (H1 FY27) | ₹445 cr |
| Asset turnover | 1.7x on fixed asset base |
| Volume growth | 4% YoY in Q2; ~7–7.5% YoY in H1 |
| Phase 1 capacity expansion | Completed as of 30 Sep 2026; installed capacity increased from 48,000 MTPA to 54,000 MTPA |
| PRIGIV JV revenue | ~₹28 cr in Q2, with positive PBT of ~₹2 cr; H1 revenue ~₹47 cr |
| FY27 revenue guidance | 20% growth or better; confident of being close to ₹4,000 cr, maybe ₹3,750 cr |
| Interim dividend | ₹5 per share, first ever interim dividend |